Samer Gawrieh, MD
Gastroenterology · Indianapolis, INNPI 1720039688
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $78,213 of the $78,213 with a category attached, or 100.0%. Transmedics, Inc. accounts for 92.1% of it on its own, with 2 other manufacturers making up the rest. Among gastroenterology clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 28 payments — averaging $2793.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Transmedics, Inc.$72K
- Pfizer$4K
- Novo Nordisk$3K
Across 19 payments — averaging $2951.29 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Transmedics, Inc.$56K
What the payments were for
- Consulting fees$78,213100%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Transmedics, Inc. | 24 | $72,000 |
| Pfizer | 3 | $3,500 |
| Novo Nordisk | 1 | $2,713 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ORGAN CARE SYSTEM$72,000
How this compares
$78,213 in reported general payments places this provider in the 95th percentile of 323 gastroenterology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XifaxanRifaximin | 59 | $196,722 |
| Ursodiol | 48 | $16,097 |
| Entecavir | 12 | $8,869 |
| Nadolol | 29 | $1,287 |
| Spironolactone | 56 | $1,163 |
| Sucralfate | 15 | $768 |
| Lactulose | 20 | $600 |
| Azathioprine | 32 | $450 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 25 | $318 |
| Pantoprazole Sodium | 39 | $300 |
| ConstuloseLactulose | 11 | $199 |
| Furosemide | 54 | $188 |
| Carvedilol | 52 | $178 |
| Omeprazole | 12 | $128 |
| Prednisone | 15 | $113 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Indianapolis
- Douglas RexIndianapolis$557K
- Ajay JainIndianapolis$432K
- Monika FischerIndianapolis$258K
- Naga ChalasaniIndianapolis$255K
- Thomas ImperialeIndianapolis$188K
- Mark GromskiIndianapolis$154K
- David PoundIndianapolis$137K
- Glen LehmanIndianapolis$87K
- Stuart ShermanIndianapolis$52K
- Mohammad Al HaddadIndianapolis$43K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.